The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data.
Anticancer medicines
Health insurance
National drug price negotiation
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
14 May 2024
14 May 2024
Historique:
received:
16
02
2024
accepted:
09
05
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
14
5
2024
Statut:
epublish
Résumé
The National Drug Price Negotiation (NDPN) policy has entered a normalisation stage, aiming to alleviate, to some extent, the disease-related and economic burdens experienced by cancer patients. This study analysed the use and subsequent burden of anticancer medicines among cancer patients in a first-tier city in northeast China. We assessed the usage of 64 negotiated anticancer medicines using the data on the actual drug deployment situation, the frequency of medical insurance claims and actual medication costs. The affordability of these medicines was measured using the catastrophic health expenditure (CHE) incidence and intensity of occurrence. Finally, we used the defined daily doses (DDDs) and defined daily doses cost (DDDc) as indicators to evaluate the actual use of these medicines in the region. During the study period, 63 of the 64 medicines were readily available. From the perspective of drug usage, the frequency of medical insurance claims for negotiated anticancer medicines and medication costs showed an increasing trend from 2018 to 2021. Cancer patients typically sought medical treatment at tertiary hospitals and purchased medicines at community pharmacies. The overall quantity and cost of medications for patients covered by the Urban Employee Basic Medical Insurance (UEBMI) were five times higher than those covered by the Urban and Rural Resident Medical Insurance (URRMI). The frequency of medical insurance claims and medication costs were highest for lung and breast cancer patients. Furthermore, from 2018 to 2021, CHE incidence showed a decreasing trend (2.85-1.60%) under urban patients' payment capability level, but an increasing trend (11.94%-18.42) under rural patients' payment capability level. The average occurrence intensities for urban (0.55-1.26 times) and rural (1.27-1.74 times) patients showed an increasing trend. From the perspective of drug utilisation, the overall DDD of negotiated anticancer medicines showed an increasing trend, while the DDDc exhibited a decreasing trend. This study demonstrates that access to drugs for urban cancer patients has improved. However, patients' medical behaviours are affected by some factors such as hospital level and type of medical insurance. In the future, the Chinese Department of Health Insurance Management should further improve its work in promoting the fairness of medical resource distribution and strengthen its supervision of the nation's health insurance funds.
Sections du résumé
BACKGROUND
BACKGROUND
The National Drug Price Negotiation (NDPN) policy has entered a normalisation stage, aiming to alleviate, to some extent, the disease-related and economic burdens experienced by cancer patients. This study analysed the use and subsequent burden of anticancer medicines among cancer patients in a first-tier city in northeast China.
METHODS
METHODS
We assessed the usage of 64 negotiated anticancer medicines using the data on the actual drug deployment situation, the frequency of medical insurance claims and actual medication costs. The affordability of these medicines was measured using the catastrophic health expenditure (CHE) incidence and intensity of occurrence. Finally, we used the defined daily doses (DDDs) and defined daily doses cost (DDDc) as indicators to evaluate the actual use of these medicines in the region.
RESULTS
RESULTS
During the study period, 63 of the 64 medicines were readily available. From the perspective of drug usage, the frequency of medical insurance claims for negotiated anticancer medicines and medication costs showed an increasing trend from 2018 to 2021. Cancer patients typically sought medical treatment at tertiary hospitals and purchased medicines at community pharmacies. The overall quantity and cost of medications for patients covered by the Urban Employee Basic Medical Insurance (UEBMI) were five times higher than those covered by the Urban and Rural Resident Medical Insurance (URRMI). The frequency of medical insurance claims and medication costs were highest for lung and breast cancer patients. Furthermore, from 2018 to 2021, CHE incidence showed a decreasing trend (2.85-1.60%) under urban patients' payment capability level, but an increasing trend (11.94%-18.42) under rural patients' payment capability level. The average occurrence intensities for urban (0.55-1.26 times) and rural (1.27-1.74 times) patients showed an increasing trend. From the perspective of drug utilisation, the overall DDD of negotiated anticancer medicines showed an increasing trend, while the DDDc exhibited a decreasing trend.
CONCLUSION
CONCLUSIONS
This study demonstrates that access to drugs for urban cancer patients has improved. However, patients' medical behaviours are affected by some factors such as hospital level and type of medical insurance. In the future, the Chinese Department of Health Insurance Management should further improve its work in promoting the fairness of medical resource distribution and strengthen its supervision of the nation's health insurance funds.
Identifiants
pubmed: 38745323
doi: 10.1186/s12889-024-18820-3
pii: 10.1186/s12889-024-18820-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1309Subventions
Organisme : Liaoning Provincial Department of Education
ID : LJKMR20221296
Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
World Health Organization (WHO). Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2019. WHO. 2020. Accessed December 11, 2020.
Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783–91.
doi: 10.1097/CM9.0000000000001474
pubmed: 33734139
Prasad V, De Jesús K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017;14(6):381–90.
doi: 10.1038/nrclinonc.2017.31
pubmed: 28290490
Blackwell K, Gligorov J, Jacobs I, Twelves C. The Global need for a Trastuzumab Biosimilar for patients with HER2-Positive breast Cancer. Clin Breast Cancer. 2018;18(2):95–113.
doi: 10.1016/j.clbc.2018.01.006
pubmed: 29525430
Doshi JA, Li P, Huo H, Pettit AR, Armstrong KA. Association of Patient out-of-Pocket costs with prescription abandonment and Delay in Fills of Novel oral Anticancer agents. J Clin Oncol. 2018;36(5):476–82.
doi: 10.1200/JCO.2017.74.5091
pubmed: 29261440
Benjamin L, Buthion V, Vidal-Trécan G, Briot P. Impact of the healthcare payment system on patient access to oral anticancer drugs: an illustration from the French and United States contexts. BMC Health Serv Res. 2014;14:274.
doi: 10.1186/1472-6963-14-274
pubmed: 24950778
pmcid: 4082413
Scherpereel A, Durand-Zaleski I, Cotté FE, Fernandes J, Debieuvre D, Blein C, Gaudin AF, Tournier C, Vainchtock A, Chauvin P, et al. Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study. BMC Cancer. 2018;18(1):1013.
doi: 10.1186/s12885-018-4958-5
pubmed: 30348130
pmcid: 6196460
IQVIA Institute. Global Oncology Trends 2021[EB/OL](2022-2-6)(2024-1-3). https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2021 .
Huang H-Y, Shi J-F, Guo L-W, Zhu X-Y, Wang L, Liao X-Z, Liu G-X, Bai Y-N, Mao A-Y, Ren J-S. Expenditure and financial burden for common cancers in China: a hospital-based multicentre cross-sectional study. Lancet. 2016;388:S10.
doi: 10.1016/S0140-6736(16)31937-7
Li X, Cai H, Wang C, Guo C, He Z, Ke Y. Economic burden of gastrointestinal cancer under the protection of the New Rural Cooperative Medical Scheme in a region of rural China with high incidence of oesophageal cancer: cross-sectional survey. Trop Med Int Health. 2016;21(7):907–16.
doi: 10.1111/tmi.12715
pubmed: 27125226
Zhang X, Liu S, Liu Y, Du J, Fu W, Zhao X, Huang W, Zhao X, Liu G, Mao Z et al. Economic Burden for Lung Cancer survivors in Urban China. Int J Environ Res Public Health 2017, 14(3).
Mingge X, Jingyu W, Qi L, Zhe Z, Qing R. Promoting Access to innovative Anticancer Medicines: a review of drug price and national reimbursement negotiation in China. Inquiry. 2023;60:469580231170729.
pubmed: 37171066
Tang M, Song P, He J. Progress on drug pricing negotiations in China. Biosci Trends. 2020;13(6):464–8.
doi: 10.5582/bst.2019.01339
pubmed: 31875587
National Healthcare Security Administration, National Health Commission of the People’s Republic of China. Guiding Opinions on Establishing and Improving the Dual-Channel Management Mechanism for National Medical Insurance Negotiation Drugs[EB/OL]. http://www.nhsa.coy.cn/at/2021/5/10/at375023.html ,2022-12-28.
Huiqun J, Xin L, Feng H. Availability and affordability of national medical insurance negotiated innovative anticancer drugs in Changzhou. Chin J Pharmacovigil. 2021;18(11):1075.
Huang C, Ung COL, Wushouer H, Bai L, Li X, Guan X, Shi L. Trends of negotiated targeted anticancer medicines use in China: an interrupted time series analysis. Int J Health Policy Manage. 2022;11(8):1489.
Liu Y, Yi H, Fang K, Bao Y, Li X. Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: an interrupted time series analysis. Front Public Health. 2022;10:942638.
doi: 10.3389/fpubh.2022.942638
pubmed: 35937254
pmcid: 9353396
Zhang Y, Wushouer H, Han S, Fu M, Guan X, Shi L, Wagner A. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China. BMJ Global Health 2021, 6(7).
Liu J, Zhang X, Wang B, Dai H, Dou D, Fang W. Trends in anti-HER2 drugs consumption and influencing factors. Front Public Health. 2022;10:944071.
doi: 10.3389/fpubh.2022.944071
pubmed: 36159303
pmcid: 9493110
Zhu H, Zhu J, Zhou Y, Shan L, Li C, Cui Y, Kang Z, Jiao M, Liu H, Gao L. Impact of the national reimbursement drug list negotiation policy on accessibility of anticancer drugs in China: an interrupted time series study. Front Public Health. 2022;10:921093.
doi: 10.3389/fpubh.2022.921093
pubmed: 35844892
pmcid: 9283976
Sun Y, Zhu Z, Zhang J, Han P, Qi Y, Wang X, Yang L. Impacts of national drug price negotiation on expenditure, volume, and availability of targeted anti-cancer drugs in China: an interrupted time series analysis. Int J Environ Res Public Health. 2022;19(8):4578.
doi: 10.3390/ijerph19084578
pubmed: 35457445
pmcid: 9025142
Cai L, Tao T, Li H, Zhang Z, Zhang L, Li X. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: a controlled interrupted time series study. J Global Health 2022, 12.
Fang W, Xu X, Zhu Y, Dai H, Shang L, Li X. Impact of the national health insurance coverage policy on the utilisation and accessibility of innovative anti-cancer medicines in China: an interrupted time-series study. Front Public Health. 2021;9:714127.
doi: 10.3389/fpubh.2021.714127
pubmed: 34422752
pmcid: 8377668
Diao Y, Qian J, Liu Y, Zhou Y, Wang Y, Ma H, Wang X, Luo R, Wagner A, Sun J. How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China: an interrupted time-series study. J Global Health 2019, 9(2).
Ding Y, Zheng C, Wei X, Zhang Q, Sun Q. The impacts of the National Medication Price-negotiated policy on the financial burden of cancer patients in Shandong province, China: an interrupted time series analysis. BMC Public Health. 2022;22(1):2363.
doi: 10.1186/s12889-022-14525-7
pubmed: 36527037
pmcid: 9756446
Zhang X, Liu S, Liu Y, Du J, Fu W, Zhao X, Huang W, Zhao X, Liu G, Mao Z. Economic burden for lung cancer survivors in urban China. Int J Environ Res Public Health. 2017;14(3):308.
doi: 10.3390/ijerph14030308
pubmed: 28294998
pmcid: 5369144
Li Y, Wu Q, Xu L, Legge D, Hao Y, Gao L, Ning N, Wan G. Factors affecting catastrophic health expenditure and impoverishment from medical expenses in China: policy implications of universal health insurance. Bull World Health Organ. 2012;90:664–71.
doi: 10.2471/BLT.12.102178
pubmed: 22984311
pmcid: 3442391
Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J, Murray CJ. Household catastrophic health expenditure: a multicountry analysis. Lancet. 2003;362(9378):111–7.
doi: 10.1016/S0140-6736(03)13861-5
pubmed: 12867110
Li H. Evaluation of changes in the availability and affordability of anti-tumor drugs before and after the implementation of the drug price negotiation policy. in Shandong Province[D],Shandong University; 2022.
Liu C, Liu Z-m, Nicholas S, Wang J. Trends and determinants of catastrophic health expenditure in China 2010–2018: a national panel data analysis. BMC Health Serv Res. 2021;21(1):526.
doi: 10.1186/s12913-021-06533-x
pubmed: 34051762
pmcid: 8164806
Organization WH. Collaborating centre for drug statistics methodology, guidelines for ATC classification and DDD assignment. WHO Collaborating Centre Drug Stat Methodol 2000, 18.
Li C, Zhou J, Xu J, Hu R, He C, Li F. Analysis on the availability of state-negotiated drugs in S Province under the Dual Channel Model. China Health Insurance 2022, (11):54–9.
Sun H, Cao R, Ren J, Cao Z. Effect and Prospect of the dual-channel management mechanism of National MedicaInsurance Negotiation drugs. China Health Insurance 2023, (01):12–5.
Bai L, Wushouer H, Huang C, Luo Z, Guan X, Shi L. Health care utilization and costs of patients with prostate cancer in China based on national health insurance database from 2015 to 2017. Front Pharmacol. 2020;11:719.
doi: 10.3389/fphar.2020.00719
pubmed: 32587512
pmcid: 7299164
Diao Y, Lin M, Xu K, Huang J, Wu X, Li M, Sun J, Li H. How government health insurance coverage of novel anti-cancer medicines benefited patients in China–a retrospective analysis of hospital clinical data. BMC Health Serv Res. 2021;21(1):1–9.
doi: 10.1186/s12913-021-06840-3
Glode AE, May MB. Rising cost of Cancer Pharmaceuticals: cost issues and interventions to control costs. Pharmacotherapy. 2017;37(1):85–93.
doi: 10.1002/phar.1867
pubmed: 27862122
McKoy JM, Fitzner KA, Edwards BJ, Alkhatib M, Tigue CC, Nonzee NJ, Bolden CR, Bennett CL. Cost considerations in the management of cancer in the older patient. Oncol (Williston Park). 2007;21(7):851–7. discussion 858, 860, 862 passim.
Fang W, Xu X, Dai H, Li X. Influence of National Medical Insurance Admittance Negotiated Policy on the utilization of innovative anticancer Drugs[J]. Volume 39. HERALD OF MEDICINE; 2020. pp. 1665–72. 12.
Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14(12):1165–74.
doi: 10.1016/S1470-2045(13)70442-X
pubmed: 24131614
Matsumoto K, Hatakeyama Y, Seto K, Onishi R, Hirata K, Wu Y, Hasegawa T. Cost of illness in a super-aged society-comparison of breast, lung, and prostate cancer in Japan. BMC Geriatr. 2022;22(1):964.
doi: 10.1186/s12877-022-03683-3
pubmed: 36517755
pmcid: 9749159
Chen S, Cao Z, Prettner K, Kuhn M, Yang J, Jiao L, Wang Z, Li W, Geldsetzer P, Bärnighausen T, et al. Estimates and projections of the Global Economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 2023;9(4):465–72.
doi: 10.1001/jamaoncol.2022.7826
pubmed: 36821107
pmcid: 9951101
Vokinger KN, Hwang TJ, Daniore P, Lee CC, Tibau A, Grischott T, Rosemann TJ, Kesselheim AS. Analysis of Launch and Postapproval Cancer Drug pricing, Clinical Benefit, and Policy implications in the US and Europe. JAMA Oncol. 2021;7(9):e212026.
doi: 10.1001/jamaoncol.2021.2026
pubmed: 34196656
pmcid: 8251654
Zhang Z, Liu H, Liu X. Definition ofstandards for catastrophic health expenditure in China: based on the effect of medical expenditure on household basic living expenses[J]. Chin J Health Policy. 2022;15(11):68–74.
Gonzales F, Zheng Z, Yabroff KR. Trends in Financial Access to prescription drugs among Cancer survivors. J Natl Cancer Inst. 2018;110(2):216–9.
doi: 10.1093/jnci/djx164
pubmed: 28954298